Medanta (Global Health Ltd) is currently trading in the ₹1,300–₹1,335 range, having shown a notable run-up over the past six months, but with increased volatility in recent weeks. The stock reached a recent high near ₹1,393 and a low around ₹935 during the past year.
Fundamentally, Medanta continues to deliver robust revenue growth: annual revenues for FY25 rose to ₹3,692 crore, up approximately 13% from the previous year. Operating profitability remains strong, with margins in the 23% range and net profits exceeding ₹480 crore for the latest fiscal year. However, the most recent quarter saw a profitability dip due to a non-recurring expense, reflecting some variability in the bottom line.
On valuation, Medanta trades at a high price-to-earnings (P/E) ratio of more than 73 and a price-to-book (P/B) above 11, both of which are elevated compared to sector averages. This premium reflects market optimism about its growth prospects but also limits the scope for immediate, significant upside. The company has a modest dividend yield and consistently generates healthy cash flows, contributing to financial strength.
The outlook from analysts remains moderately positive: one-year price targets are clustered around ₹1,300–₹1,500, with the company expected to benefit from long-term sector growth and its strong operating metrics. Near-term, the share price may consolidate after recent gains, with moves likely guided by the next round of earnings and overall market sentiment. Medanta’s key strengths are scale, profitability, and discipline, but its premium valuation requires steady execution and increasing returns to justify further appreciation.
Fundamentally, Medanta continues to deliver robust revenue growth: annual revenues for FY25 rose to ₹3,692 crore, up approximately 13% from the previous year. Operating profitability remains strong, with margins in the 23% range and net profits exceeding ₹480 crore for the latest fiscal year. However, the most recent quarter saw a profitability dip due to a non-recurring expense, reflecting some variability in the bottom line.
On valuation, Medanta trades at a high price-to-earnings (P/E) ratio of more than 73 and a price-to-book (P/B) above 11, both of which are elevated compared to sector averages. This premium reflects market optimism about its growth prospects but also limits the scope for immediate, significant upside. The company has a modest dividend yield and consistently generates healthy cash flows, contributing to financial strength.
The outlook from analysts remains moderately positive: one-year price targets are clustered around ₹1,300–₹1,500, with the company expected to benefit from long-term sector growth and its strong operating metrics. Near-term, the share price may consolidate after recent gains, with moves likely guided by the next round of earnings and overall market sentiment. Medanta’s key strengths are scale, profitability, and discipline, but its premium valuation requires steady execution and increasing returns to justify further appreciation.
Trade active
If earlier entry is mised with small SL, we can make new entry
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.